We need to work towards a future where organ on a chip technology is more accurate in mimicking the human body than any animal could ever be.Because over 110 million animals are used in experiments to develop new medicine. Organ by organ we will need to develop better alternatives than the experiments that are done on animals now.
Our spin-off company Cell4Pharma focuses on developing a model that is more accurate in mimicking the human kidney than any other animal experiment on the market.
Grab this opportunity to be part of their mission and become an investor.
Check out their crowdfunding page on Symbid here: http://www.symbid.nl/projects/427
Related news items
Saving lives with a small pump inside the heart CardiacBooster31 March 2023 Less damage to organs and a greater chance of survival after having a heart attack. That's what Radboudumc spin-off CardiacBooster is aiming to accomplish. read more
Strategic partnership Enzyre BV and Takeda for better diagnostics for bleeding disorders31 March 2023 Takeda announced to have entered into a strategic partnership with Enzyre BV, a Radboudumc spin-off company. read more
Aftermovie Investment Day 2022 and a new date for 2023!31 March 2023
Over 100 scientists, investors, and entrepreneurs came together to accelerate innovation in healthcare by creating new business opportunities and forging strong public-private partnerships.read more
Radboudumc Investment Day 202231 March 2023
Get ready for Radboudumc Investment Day 2022: October 5 in Nijmegen!read more
Joining forces increases innovation Janssen and Radboud31 March 2023
Dr. Eng Kinga Matuła (KM), specialist in single-cell multi-omics and Jeroen Van Houdt (JH), Omics group leader at Janssen Pharmaceutica, answer three pressing questions about the successful collaboration in the single-cell technology project.read more